A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.JAKを阻害できる、式Iによる新規なピラゾロピリジンが開示され、これらの化合物は医薬組成物として製造でき、ヒトを含む哺乳動物の種々の病態、非限定的な例として、アレルギー、炎症性病態、自己免疫疾患、増殖性疾患、移植片拒絶、軟骨代謝回転の異常を伴う疾患、先天性軟骨形成異常、及び／又はIL6若しくはインターフェロンの分泌過多に関連する疾患の予防及び治療に使用できる。【化１】【選択図】なし
